Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXL1717 in Recurrent Malignant Astrocytomas
NCT01721577Phase 2Terminated
- Sponsor
- Rush University Medical Center
- Start
- Dec 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of picropodophyllin in malignant astrocytoma, glioblastoma (GBM), Gliosarcoma (GS) and 4 more, sponsored by Rush University Medical Center. Primary endpoints: Recommended Phase II Dose at 8 months and Antitumor Effect at 24 weeks. Started Dec 2012; status: terminated.
02
Drugs
picropodophyllin
03
Conditions
malignant astrocytomaglioblastoma (GBM)Gliosarcoma (GS)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on NCT01721577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721577.